From Nasdaq, Inc.:

Wall Street analysts are bullish on Intellia Therapeutics (NASDAQ: NTLA), estimating it will rise by 157% over the next 12 months. With two phase 3 clinical programs aiming to correct heritable rare illnesses and projections of a $11 billion market by 2029, Intellia has potential for significant growth. However, financial concerns, a competitive market, and the need to fight incumbents raises questions about the accuracy of these projections and the potential for Intellia to deliver. Despite high expectations, Intellia is an ascendant biotech and can be a good investment, even if it doesn’t soar as high as the analysts hope.



Read more: Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?